title: Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy.
abstract: The number of people living with HIV and AIDS (PLWHA) reached to almost 40 million, half of which are under antiretroviral treatment (ART). Although the introduction of this therapy significantly improved the life span and quality of PLWHA, metabolic complications of these people remains to be an important issue. These metabolic complications include hyperlipidemia, abnormal fat redistribution and diabetes mellitus, which are defined as lipodystrophy syndrome. Glucagon-like peptide-1 (GLP-1) is a neuropeptide secreted from intestinal L cells and recently developed GLP-1 receptor agonists (GLP-1RAs) stimulate insulin secretion, improve weight control and reduce cardiovascular outcomes. This class of drugs may be a valuable medication in the treatment of HIV-associated metabolic adverse effects and extend the life expectancy of patients infected with HIV.
authors: Department of Urology, Istanbul Training & Research Hospital, Istanbul, Turkey.
authors: Mehmet Gokhan
authors: MG
authors: Culha
authors: Department of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey.
authors: Ahmet Cagkan
authors: AC
authors: Inkaya
authors: Novo Nordisk Turkey, CMRQ Department, Istanbul, Turkey.
authors: Emre
authors: E
authors: Yildirim
authors: Department of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey.
authors: Serhat
authors: S
authors: Unal
authors: Department of Urology, Bagcilar Training & Research Hospital, Istanbul, Turkey. Electronic address: egecanserefoglu@hotmail.com.
authors: Ege Can
authors: EC
authors: Serefoglu
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight; D003920:Diabetes Mellitus / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D018450:Disease Progression; D052216:Glucagon-Like Peptide 1 / Q000819:agonists* / Q000378:metabolism; D000067757:Glucagon-Like Peptide-1 Receptor / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008017:Life Expectancy; D008060:Lipodystrophy / Q000378:metabolism; D008962:Models, Theoretical; D050151:Subcutaneous Fat / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1